Cell Death and Disease (May 2022)

AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis

  • Hyunjoo Kim,
  • Muhah Jeong,
  • Do-Hyeong Na,
  • Shin-Hyeon Ryu,
  • Eun Il Jeong,
  • Kwangmin Jung,
  • Jaemin Kang,
  • Ho-June Lee,
  • Taebo Sim,
  • Dae-Yeul Yu,
  • Hee Chul Yu,
  • Baik-Hwan Cho,
  • Yong-Keun Jung

DOI
https://doi.org/10.1038/s41419-022-04921-7
Journal volume & issue
Vol. 13, no. 5
pp. 1 – 11

Abstract

Read online

Abstract The RAS–BRAF signaling is a major pathway of cell proliferation and their mutations are frequently found in human cancers. Adenylate kinase 2 (AK2), which modulates balance of adenine nucleotide pool, has been implicated in cell death and cell proliferation independently of its enzyme activity. Recently, the role of AK2 in tumorigenesis was in part elucidated in some cancer types including lung adenocarcinoma and breast cancer, but the underlying mechanism is not clear. Here, we show that AK2 is a BRAF-suppressor. In in vitro assays and cell model, AK2 interacted with BRAF and inhibited BRAF activity and downstream ERK phosphorylation. Energy-deprived conditions in cell model and the addition of AMP to cell lysates strengthened the AK2-BRAF interaction, suggesting that AK2 is involved in the regulation of BRAF activity in response to cell metabolic state. AMP facilitated the AK2–BRAF complex formation through binding to AK2. In a panel of HCC cell lines, AK2 expression was inversely correlated with ERK/MAPK activation, and AK2-knockdown or -knockout increased BRAF activity and promoted cell proliferation. Tumors from HCC patients showed low-AK2 protein expression and increased ERK activation compared to non-tumor tissues and the downregulation of AK2 was also verified by two microarray datasets (TCGA-LIHC and GSE14520). Moreover, AK2/BRAF interaction was abrogated by RAS activation in in vitro assay and cell model and in a mouse model of HRASG12V-driven HCC, and AK2 ablation promoted tumor growth and BRAF activity. AK2 also bound to BRAF inhibitor-insensitive BRAF mutants and attenuated their activities. These findings indicate that AK2 monitoring cellular AMP levels is indeed a negative regulator of BRAF, linking the metabolic status to tumor growth.